Report Overview

The Australian Hypophosphatasia (HPP) Treatment Market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Hypophosphatasia (HPP) is also known as Rathbun disease is an ultra-rare metabolic genetic disorder characterized by the abnormal development of bones and teeth due to defective mineralization, a process by which bones and teeth use minerals such as calcium and phosphorus. It caused by mutations in the tissue nonspecific alkaline phosphatase (TNSALP) gene, also called the ALPL gene. Such mutations lead to low activity of this enzyme that should be breaking down a chemical called inorganic pyrophosphate that blocks mineralization, profound muscle weakness, seizures, respiratory failure and premature death.



Market Drivers

The Hypophosphatasia community are helping to bring programs that will bring new and treatment options to people with rare diseases. Currently, clinical trials are conducted, wherein a large number of organizations are actively participating in several research programs to develop novel therapies for infantile and juvenile-onset hypophosphatasia treatment.

Introduction of several novel therapy, breakthrough therapy designation, orphan drug designation for rare diseases, financial incentives and grants by the government, clinical studies on safety and efficacy of products, is expected to be the biggest hit in the hypophosphatasia market over the forecast period.

Gaps in making Hypophosphatasia (HPP) health priority, patients non-adherence to therapy regime, high therapy cost, a smaller number of approved therapies, and failure in clinical trial at the late phase are some of the factors restraining the infantile and juvenile-onset hypophosphatasia treatment market.